This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeon, Y.-T. Articles by Song, Y.-S. Search for Related Content PubMed PubMed Citation Articles by Jeon, Y.-T. Articles by Song, Y.-S.

Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer

Departments of ¹ Obstetrics and Gynecology, ² Preventive Medicine, and ³ Pathology and ⁴ Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Korea

Requests for reprints: Yong-Sang Song, Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, 28 Yongun-dong, Jongno-gu, Seoul 110-744, Korea. Phone: 82-2-760-2822; Fax: 82-2-762-3599. E-mail: yssong{at}snu.ac.kr

Cyclooxygenase-2 (COX-2) has been known to be related with various types of carcinoma, but we have insufficient knowledge about the association between COX-2 and endometrial cancer. Many have reported a close relationship between p53 expression and a poor prognosis in endometrial cancer, but it is unclear whether p53 is an independent prognostic factor. To clarify these uncertainties, we examined the expressions of COX-2 and p53 in endometrial cancer tissues. The study was carried on 152 endometrial cancer patients who had operation at Seoul National University Hospital. Paraffin-embedded tissue blocks were sectioned and immunostained using monoclonal anti-COX-2 and anti-p53 antibodies. Twenty-seven (17.8%) specimens stained as COX-2 positive. COX-2 positivity was more frequently observed in postmenopausal patients than in premenopausal patients (8.8% versus 25.0%; P = 0.009). However, COX-2 positivity did not show a statistically significant association with any other clinicopathologic characteristic (parity, body mass index, histotype, International Federation of Gynecology and Obstetrics stage, grade, lymph node metastasis, deep myometrial invasion, or p53 overexpression). Thirty-one (20.4%) specimens showed p53 overexpression and this was significantly correlated with an advanced stage (P = 0.001), poor differentiation (P < 0.001), lymph node metastasis (P = 0.012), and deep myometrial invasion (P < 0.001). Multivariate Cox regression analysis showed that advanced stage was an independent prognostic factor of survival, but p53 overexpression was not. COX-2 may be associated with endometrial cancer carcinogenesis during the postmenopausal period but not with tumor aggressiveness and p53 overexpression. The p53 overexpression was found to be strongly associated with endometrial cancer aggressiveness.

This article has been cited by other articles:

				Y.-C. SONG, S.-H. KIM, Y.-S. JUHNN, and Y.-S. SONG Apoptotic Effect of Celecoxib Dependent Upon p53 Status in Human Ovarian Cancer Cells Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 26 - 34. [Abstract] [Full Text] [PDF]

				Y.-T. JEON, S. Y. PARK, Y.-B. KIM, J. W. KIM, N.-H. PARK, S.-B. KANG, H.-P. LEE, and Y.-S. SONG Aromatase Expression Was Not Detected by Immunohistochemistry in Endometrial Cancer Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 70 - 75. [Abstract] [Full Text] [PDF]

				F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss Inflammation and Endometrial Cancer: A Hypothesis Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2840 - 2847. [Abstract] [Full Text] [PDF]